At present, Prostate Specific Antigen (PSA) is still the core tumor marker used for diagnosing PCa in clinical practice, combined with Prostatic Acid Phosphatase (PAP) and Prostate Cancer Antigen 3(PCA3) for joint evaluation. Here, KLK3 is linked to posterior cortical atrophy.